Tarsus Pharmaceuticals Inc Cash Flow Conversion Efficiency
Tarsus Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) has a cash flow conversion efficiency ratio of 0.193x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($66.77 Million) by net assets ($346.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tarsus Pharmaceuticals Inc (2018–2025)
Cash flow conversion efficiency of Tarsus Pharmaceuticals Inc from 2018 to 2025. This chart illustrates how Tarsus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tarsus Pharmaceuticals Inc share price for real-time trading data and today's change.
Tarsus Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Tarsus Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tarsus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tarsus Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Tarsus Pharmaceuticals Inc (TARS) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OSI Systems Inc
NASDAQ:OSIS
|
0.074x |
|
Grupo Cementos de Chihuahua S.A.B. de C.V
MX:GCC
|
0.069x |
|
WNS Holdings Ltd
NYSE:WNS
|
0.037x |
|
Bank of Queensland Ltd
AU:BOQ
|
0.082x |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739
|
0.068x |
|
Jack Sewing
SHG:603337
|
0.054x |
|
Sinch AB
ST:SINCH
|
0.040x |
|
Beijing Sifang Automation Co Ltd
SHG:601126
|
0.024x |
Annual Cash Flow Conversion Efficiency for Tarsus Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Tarsus Pharmaceuticals Inc from 2018 to 2025. Review cash generation quality of Tarsus Pharmaceuticals Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $343.43 Million | $-12.45 Million | -0.036x | +90.20% |
| 2024-12-31 | $224.53 Million | $-83.03 Million | -0.370x | +38.00% |
| 2023-12-31 | $196.99 Million | $-117.49 Million | -0.596x | -134.66% |
| 2022-12-31 | $192.90 Million | $-49.03 Million | -0.254x | -1230.69% |
| 2021-12-31 | $166.73 Million | $3.75 Million | 0.022x | +117.65% |
| 2020-12-31 | $165.98 Million | $-21.14 Million | -0.127x | -120.82% |
| 2019-12-31 | $-6.00 Million | $-3.67 Million | 0.612x | -29.99% |
| 2018-12-31 | $-1.35 Million | $-1.18 Million | 0.874x | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more